Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Rapid initiation of cyclosporine and eltrombopag ahead of definitive treatment decreases autoimmunity and expedites marrow recovery in a prospective phase II trial

View Full Paper
Ask AI
Bookmark
Share

Authors

NLNicholas C.J. LeeJSJeanine SuperataBKByeong‐Teck Kang

Discussion

Loading...

Member takes

Overview

Phase II trial shows rapid initiation of cyclosporine and eltrombopag improves hematologic recovery in severe aplastic anemia, indicating safer treatment pathways.

Key Points

  • Evaluate the feasibility and safety of rapid cyclosporine and eltrombopag initiation in severe aplastic anemia patients.
  • Phase II clinical trial with 45 treatment-naive patients
  • Initiation of low dose cyclosporine and eltrombopag following eligibility confirmation
  • Composite rates of treatment-related serious adverse events measured for feasibility and safety
  • 4% rate of no treatment-related serious adverse events
  • Median ANC increased from 0.3 to 0.42 by Day 1 of hATG administration
  • 2-year high-risk clonal evolution rate was 3%

Cite This Study

Lee et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e368https://doi.org/10.1182/blood-2025-979
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Adding eltrombopag to immunosuppressive treatment with cyclosporine as front-line therapy for moderate aplastic anemia improves trilineage hematologic response: One-year analysis of the randomised, placebo-controlled, double-blind Phase III trial eltrombopag for moderate aplastic anemia (EMAA Trial)2025
  2. 2A novel reduced-toxicity conditioning regimen with busulfan/fludarabine/cyclophosphamide/anti-thymocyte globulin for severe aplastic anemia2025
  3. 3Low-dose cyclophosphamide combined with standard immunosuppressive therapy improves early response rates in severe aplastic anemia2026 · 1 citations
  4. 4Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study2021 · 111 citations
  5. 5Long-term outcomes of intensive immunosuppressive therapy combined with eltrombopag in patients with severe aplastic anemia2025